Evogene Shareholders Approve All Proposals at Annual Meeting
Ticker: EVGN · Form: 6-K · Filed: Aug 18, 2025 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
Evogene shareholders backed all proposals at the AGM, clearing the path for management's plans.
AI Summary
Evogene Ltd. announced on August 18, 2025, that its shareholders approved all proposals at the annual general meeting. This meeting, which was adjourned for one week, confirmed the company's strategic direction and governance.
Why It Matters
Shareholder approval of all proposals indicates strong support for the company's management and strategic plans, potentially leading to smoother execution of future business initiatives.
Risk Assessment
Risk Level: low — The filing is a routine announcement of shareholder meeting outcomes, with no new financial or operational risks introduced.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- August 18, 2025 (date) — Date of annual general meeting
FAQ
What was the purpose of the August 18, 2025 meeting?
The meeting was the annual general meeting of shareholders for Evogene Ltd., where proposals were brought before them for approval.
Were all proposals approved by the shareholders?
Yes, the shareholders of Evogene Ltd. approved all proposals brought before them at the annual general meeting.
Was the annual general meeting held on its originally scheduled date?
No, the meeting was held on August 18, 2025, following a one-week adjournment from the original meeting date.
What is the company's principal executive office address?
The principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Which form does Evogene Ltd. file its annual reports under?
Evogene Ltd. files its annual reports under Form 20-F.
Filing Stats: 327 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-08-18 16:01:07
Filing Documents
- zk2533671.htm (6-K) — 10KB
- 0001178913-25-002965.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd. (the " Registrant " or the " Company ") hereby announces that the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders held on August 18, 2025 (following a one-week adjournment from the original meeting date) (the " Meeting "), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (" SEC "), on June 17, 2025, and sent in connection with the Meeting. The contents of this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565 ), and Form S-8 (File Nos. 333-193788 , 333-201443 , 333-203856 , 333-259215 and 333-286197 ) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 18, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer